Texas Capital Bank Wealth Management Services Inc reduced its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 92.4% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 7,599 shares of the company’s stock after selling 92,447 shares during the quarter. Texas Capital Bank Wealth Management Services Inc’s holdings in Zoetis were worth $531,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in the business. Minneapolis Portfolio Management Group LLC lifted its holdings in shares of Zoetis by 233.3% during the 3rd quarter. Minneapolis Portfolio Management Group LLC now owns 303,853 shares of the company’s stock worth $21,218,000 after acquiring an additional 212,691 shares during the period. Nicholson Wealth Management Group LLC boosted its position in shares of Zoetis by 9.9% in the third quarter. Nicholson Wealth Management Group LLC now owns 17,886 shares of the company’s stock worth $1,249,000 after acquiring an additional 1,610 shares during the last quarter. Hantz Financial Services Inc. grew its holdings in Zoetis by 4.4% in the third quarter. Hantz Financial Services Inc. now owns 84,613 shares of the company’s stock valued at $5,909,000 after purchasing an additional 3,568 shares during the period. Royce & Associates LP purchased a new stake in Zoetis in the third quarter valued at approximately $498,000. Finally, Danske Bank A S grew its holdings in Zoetis by 6.6% in the third quarter. Danske Bank A S now owns 295,594 shares of the company’s stock valued at $20,641,000 after purchasing an additional 18,268 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
ZTS has been the subject of several research reports. Piper Sandler lowered their price objective on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. Weiss Ratings raised Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 29th. Citigroup cut their target price on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Morgan Stanley reduced their target price on Zoetis from $85.00 to $82.00 and set an “overweight” rating on the stock in a report on Thursday, October 29th. Finally, BNP Paribas Exane reduced their target price on Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday, August 11th. Eight analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $101.25.
Zoetis Price Performance
Shares of ZTS stock opened at $84.22 on Tuesday. The firm has a fifty day simple moving average of $76.45 and a 200-day simple moving average of $91.37. The company has a current ratio of 2.35, a quick ratio of 1.40 and a debt-to-equity ratio of 2.51. The company has a market capitalization of $34.22 billion, a PE ratio of 14.32, a price-to-earnings-growth ratio of 1.20 and a beta of 0.67. Zoetis Inc. has a twelve month low of $68.77 and a twelve month high of $132.49.
Zoetis (NYSE:ZTS – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $1.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.51 by $0.24. Zoetis had a return on equity of 85.90% and a net margin of 26.15%. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.30 billion. During the same period in the previous year, the company earned $1.70 earnings per share. The company’s revenue for the quarter was down 1.3% compared to the same quarter last year. Equities research analysts anticipate that Zoetis Inc. will post 6.29 earnings per share for the current fiscal year.
Zoetis Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Shareholders of record on Friday, October 30th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Friday, October 30th. Zoetis’s dividend payout ratio is 36.05%.
About Zoetis
Zoetis is an animal health company that discovers, develops, manufactures and markets medicines, vaccines, diagnostic products and other services for animals. Its products support both companion animals, such as dogs and cats, and livestock, including cattle, pigs, poultry, sheep and fish. The company’s offerings include treatments for pain, infections and skin conditions, as well as vaccines, parasiticides, diagnostic tools and genetic testing services. Zoetis serves veterinarians, livestock producers and other animal health professionals around the world.
See Also
- Five stocks we like better than Zoetis
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
